Header Logo

Connection

Joan Walker to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications Joan Walker has written about Neoplasm Recurrence, Local.
Joan Walker
Connection Strength
3.291
Neoplasm Recurrence, Local
  1. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014 Apr; 133(1):23-7.
    View in: PubMed
    Score: 0.367
  2. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Mar; 120(3):459-63.
    View in: PubMed
    Score: 0.291
  3. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2025 Aug 21; 393(8):774-785.
    View in: PubMed
    Score: 0.199
  4. A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study. Gynecol Oncol. 2025 Apr; 195:66-74.
    View in: PubMed
    Score: 0.196
  5. Nail unit melanoma treated with Mohs micrographic surgery: Technique, local recurrence rate, and surgical outcomes. J Am Acad Dermatol. 2025 May; 92(5):1072-1079.
    View in: PubMed
    Score: 0.194
  6. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
    View in: PubMed
    Score: 0.160
  7. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
    View in: PubMed
    Score: 0.157
  8. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939.
    View in: PubMed
    Score: 0.135
  9. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.
    View in: PubMed
    Score: 0.123
  10. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
    View in: PubMed
    Score: 0.115
  11. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791.
    View in: PubMed
    Score: 0.113
  12. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
    View in: PubMed
    Score: 0.112
  13. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86.
    View in: PubMed
    Score: 0.106
  14. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32.
    View in: PubMed
    Score: 0.103
  15. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.
    View in: PubMed
    Score: 0.084
  16. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012 Nov; 127(2):345-50.
    View in: PubMed
    Score: 0.082
  17. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):367-71.
    View in: PubMed
    Score: 0.079
  18. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700.
    View in: PubMed
    Score: 0.079
  19. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Feb; 120(2):224-8.
    View in: PubMed
    Score: 0.074
  20. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol. 2011 Mar; 120(3):454-8.
    View in: PubMed
    Score: 0.073
  21. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. Gynecol Oncol. 2008 Mar; 108(3):584-90.
    View in: PubMed
    Score: 0.059
  22. Low local recurrence rates after Mohs micrographic surgery for cutaneous squamous cell carcinoma of the nail unit. J Am Acad Dermatol. 2024 04; 90(4):832-833.
    View in: PubMed
    Score: 0.045
  23. Perianal and anal skin cancers treated with Mohs micrographic surgery and interdisciplinary care: Local recurrence rates and patient-reported outcomes. J Am Acad Dermatol. 2023 12; 89(6):1283-1285.
    View in: PubMed
    Score: 0.044
  24. A retrospective case series of Mohs micrographic surgery and interdisciplinary management of female genital skin cancers: Local recurrence rates and patient-reported outcomes. J Am Acad Dermatol. 2023 08; 89(2):301-308.
    View in: PubMed
    Score: 0.043
  25. Frequency and reliability of histologic subtype classification in invasive and in situ melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2023 05; 88(5):1211-1214.
    View in: PubMed
    Score: 0.042
  26. Desmoplastic melanoma treated with wide local excision or Mohs micrographic surgery: Rates of positive margins, local recurrence, and repeat surgeries. J Am Acad Dermatol. 2022 12; 87(6):1376-1378.
    View in: PubMed
    Score: 0.041
  27. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecol Oncol. 2021 11; 163(2):392-397.
    View in: PubMed
    Score: 0.038
  28. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 11; 151(2):257-263.
    View in: PubMed
    Score: 0.031
  29. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242.
    View in: PubMed
    Score: 0.028
  30. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Mar; 132(3):585-92.
    View in: PubMed
    Score: 0.023
  31. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007 Nov; 197(5):503.e1-6.
    View in: PubMed
    Score: 0.015
  32. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Sep; 102(3):432-9.
    View in: PubMed
    Score: 0.013
  33. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
    View in: PubMed
    Score: 0.012
  34. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.009
  35. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol. 1990 Jun; 75(6):1016-22.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.